Rezolute Shares Rise After Recommendation to Continue Phase 3 Ersodetug Study

Dow Jones

Apr 23, 2025

By Chris Wack

Rezolute shares were up 29%, to $4, after the company said an independent data monitoring committee recommended the continuation of a Phase 3 Ersodetug study in patients with congenital hyperinsulinism without an increase in the study sample size.

The biopharmaceutical company said it expects to complete enrollment next month, with topline results anticipated in December.

The interim analysis of the Phase 3 study was based on a pre-specified analysis of the primary study endpoint--hypoglycemia events--after half of enrolled patients completed the primary assessments.

Rezolute said the analysis was intended to evaluate for study a potential sample size increase, for purposes of optimizing the study power and statistical confidence in the final analysis outcomes.

Rezolute also said an underwritten offering of 20.8 million shares priced at $3.25 a share. Pre-funded warrants to buy up to 6.9 million shares priced at $3.249 per pre-funded warrant. Proceeds from the underwritten offering before deducting underwriting discounts and commissions and other offering expenses are expected to be $90 million.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

April 23, 2025 10:44 ET (14:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2529633017"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2529633017\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2529633017?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-23 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529633017","market":"other","top_or_hot":-1,"title":"Rezolute Shares Rise After Recommendation to Continue Phase 3 Ersodetug Study","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Rezolute shares were up 29%, to $4, after the company said an independent data monitoring committee recommended the continuation of a Phase 3 Ersodetug study in patients with congenital hyperinsulinism without an increase in the study sample size. \n</p>\n<p>\n  The biopharmaceutical company said it expects to complete enrollment next month, with topline results anticipated in December. \n</p>\n<p>\n  The interim analysis of the Phase 3 study was based on a pre-specified analysis of the primary study endpoint--hypoglycemia events--after half of enrolled patients completed the primary assessments. \n</p>\n<p>\n  Rezolute said the analysis was intended to evaluate for study a potential sample size increase, for purposes of optimizing the study power and statistical confidence in the final analysis outcomes. \n</p>\n<p>\n  Rezolute also said an underwritten offering of 20.8 million shares priced at $3.25 a share. Pre-funded warrants to buy up to 6.9 million shares priced at $3.249 per pre-funded warrant. Proceeds from the underwritten offering before deducting underwriting discounts and commissions and other offering expenses are expected to be $90 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2025 10:44 ET (14:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rezolute Shares Rise After Recommendation to Continue Phase 3 Ersodetug Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRezolute Shares Rise After Recommendation to Continue Phase 3 Ersodetug Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-23 22:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Rezolute shares were up 29%, to $4, after the company said an independent data monitoring committee recommended the continuation of a Phase 3 Ersodetug study in patients with congenital hyperinsulinism without an increase in the study sample size. \n</p>\n<p>\n  The biopharmaceutical company said it expects to complete enrollment next month, with topline results anticipated in December. \n</p>\n<p>\n  The interim analysis of the Phase 3 study was based on a pre-specified analysis of the primary study endpoint--hypoglycemia events--after half of enrolled patients completed the primary assessments. \n</p>\n<p>\n  Rezolute said the analysis was intended to evaluate for study a potential sample size increase, for purposes of optimizing the study power and statistical confidence in the final analysis outcomes. \n</p>\n<p>\n  Rezolute also said an underwritten offering of 20.8 million shares priced at $3.25 a share. Pre-funded warrants to buy up to 6.9 million shares priced at $3.249 per pre-funded warrant. Proceeds from the underwritten offering before deducting underwriting discounts and commissions and other offering expenses are expected to be $90 million. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2025 10:44 ET (14:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RZLT","symbol_name":"Rezolute, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2529633017","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529633017","pubTimestamp":1745419440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Rezolute shares were up 29%, to $4, after the company said an independent data monitoring committee recommended the continuation of a Phase 3 Ersodetug study in patients with congenital hyperinsulinism without an increase in the study sample size.The biopharmaceutical company said it expects to complete enrollment next month, with topline results anticipated in December.The interim analysis of the Phase 3 study was based on a pre-specified analysis of the primary study endpoint--hypoglycemia events--after half of enrolled patients completed the primary assessments.Rezolute said the analysis was intended to evaluate for study a potential sample size increase, for purposes of optimizing the study power and statistical confidence in the final analysis outcomes.Rezolute also said an underwritten offering of 20.8 million shares priced at $3.25 a share. Pre-funded warrants to buy up to 6.9 million shares priced at $3.249 per pre-funded warrant. Proceeds from the underwritten offering before ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RZLT":"Rezolute, Inc.","BK4139":"生物科技"},"translate_title":"建议继续3期Ersodetug研究后，Rezolute股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RZLT":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Rezolute shares were up 29%, to $4, after the company said an independent data monitoring committee recommended the continuation of a Phase 3 Ersodetug study in patients with congenital hyperinsulinism without an increase in the study sample size. \n\n\n  The biopharmaceutical company said it expects to complete enrollment next month, with topline results anticipated in December. \n\n\n  The interim analysis of the Phase 3 study was based on a pre-specified analysis of the primary study endpoint--hypoglycemia events--after half of enrolled patients completed the primary assessments. \n\n\n  Rezolute said the analysis was intended to evaluate for study a potential sample size increase, for purposes of optimizing the study power and statistical confidence in the final analysis outcomes. \n\n\n  Rezolute also said an underwritten offering of 20.8 million shares priced at $3.25 a share. Pre-funded warrants to buy up to 6.9 million shares priced at $3.249 per pre-funded warrant. Proceeds from the underwritten offering before deducting underwriting discounts and commissions and other offering expenses are expected to be $90 million. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2025 10:44 ET (14:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}